European Region
The Institut Pasteur considers Europe a core priority, convinced that 21st century health challenges (new pandemics, antimicrobial resistance, climate change-related disease emergence) can only be met on the scale of a united and ambitious continent.
This has prompted the Institut Pasteur to play an active role in shaping the European scientific agenda. As such, it advocates for European research and public health policies that are ambitious enough to meet these challenges.
Every year, it honors this commitment by securing funding for European projects, as well as European Research Council (ERC) grants for its scientists. Each ERC grant is awarded through one of Europe's most competitive selection processes, based solely on scientific excellence. These awards prove the size and quality of the Institut Pasteur's pool of scientific talent.
Advancing Cooperation within the European Union
The Institut Pasteur is an active member of this alliance of 12 prestigious research institutions from 8 European countries striving for fair scientific cooperation with low-income countries.
Alongside Université Paris-Saclay, the Institut Pasteur is the first Core Partner of this key partnership aimed at developing European cooperation on global health education and research.
The Institut Pasteur is involved in this European university alliance strengthening links between research, training and citizenship at continental level.
Institutional cooperation in Europe
Our scientific programs in the region
The OneHealthSecure project aims to support the 23 beneficiary countries in the Mediterranean region to adapt to climate change by tackling vector-borne diseases using a One Health approach. The project builds on the unique One Health network created through the former MediLabSecure project. It targets remaining gaps in prevention and preparedness for viral vector-borne diseases. Using vector-borne diseases as a model, it aims to drive long-term recognition and implementation of One Health practices in beneficiary countries.
Delivering a Unified Research Alliance of Biomedical and public health Laboratories against Epidemics.
To achieve and maintain the highest level of EU pandemic readiness through the establishment of a consortium enabling research and development of safe and effective vaccines and monoclonal antibodies.
ACT-CHIK is a multinational research initiative strengthening Africa’s preparedness against chikungunya through vaccine research, clinical trials, and capacity building. Building on promising results from Phase I and Phase II studies of the MV-CHIK vaccine candidate, the ACT-CHIK project aims to achieve three strategic goals to address chikungunya as a public health concern in Africa.
The PvSeroRDT consortium has developed the first-ever diagnostic test to specifically target dormant hepatic forms. The POC RDT uses lateral flow technology to detect antibodies against four P. vivax proteins — key biomarkers of the parasite's dormant stage. This approach identifies recently infected individuals who may carry hypnozoites, enabling targeted treatment to prevent relapses and stop malaria transmission.
PvSTATEM aims to equip the European Union with an autonomous capacity to discover, develop and produce vaccines and monoclonal antibodies against infectious diseases with epidemic or pandemic potential.
R2D2-MH is a 5-year project co-funded by the European Commission that aims to identify risk and resilience factors associated with neurodevelopmental diversity, including Autism, ADHD or Intellectual Disability.
Sonar-Cities is funded under Horizon Europe’s Disaster-Resilient Societies cluster. The project aims to enhance the resilience of European cities in the face of health emergencies and disasters by promoting the inclusion of marginalized or excluded populations in preparedness and response efforts. Through the co-development of tools with at-risk communities, frontline responders, and local authorities, the initiative seeks to mitigate both the immediate and long-term health consequences of such crises.
YELLOW4FLAVI aims to fill the gaps in our understanding of the mechanism of action of the yellow fever 17D (YF17D) vaccine by linking the structure of the viral particle to the resulting host immune response, in order to learn about optimal vaccine design for flaviviruses in general.